BIOMAT Database Logo BIOMAT Database Logo

[The effects of isosorbide dinitrate spray on the coronary artery and its modification by the preceding chronic oral therapy with long acting isosorbide dinitrate]. 1992

T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
First Department of Medicine, Medical College of Oita.

The vasodilatory effect of a new formula of isosorbide dinitrite (ISDN) spray on the left coronary artery was studied by comparing its effects in 46 consecutive patients who subsequently received intracoronary injection with ISDN (2.5 mg). In addition, the influence long acting and ISDN for chronic cases on the vasodilatory effects of ISDN spray and on subsequent intracoronary injection of ISDN was investigated. The patients were divided into two groups, those who had had chronic oral ISDN (Group N; 29 patients) and those who had not (Group O; 17 patients). The vasodilatory effect of ISDN spray was evaluated in segments; 5, 6, 8, 11 and 12 by AHA classification and it dilated those segments by 9.9%, 13.2%, 21.5%, 15.6% and 23.5% respectively. Subsequent intracoronary injection of ISDN dilated those segments by 10.4%, 14.0%, 27.2%, 17.9% and 29.1% respectively. The differences in the degree of vasodilation caused by ISDN spray and that caused by injection in segments 8, 11, 12 were statistically significant. However, the per cent dilation of ISDN spray in segments 5 in group N was 5.9%, and 18.4% in group O, revealing a significant difference depending on previous chronic administration of long acting ISDN. We conclude that ISDN spray did dilate the coronary artery, and subsequent intracoronary administration of ISDN dilated it further in the distal portions of the left coronary artery. Long acting oral ISDN for chronic cases seemed to attenuate the vasodilatory action of ISDN.

UI MeSH Term Description Entries
D007269 Injections, Intra-Arterial Delivery of drugs into an artery. Injections, Intraarterial,Intra-Arterial Injections,Intraarterial Injections,Injection, Intra-Arterial,Injection, Intraarterial,Injections, Intra Arterial,Intra Arterial Injections,Intra-Arterial Injection,Intraarterial Injection
D007548 Isosorbide Dinitrate A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action. Cardonit 40,Dilatrate,Iso-Bid,Isodinit,Isoket,Isoket Retard-120,Isomak R,Isordil,Isotrate,Nitrosorbide,Sorbitrate,Sorbonit,Dinitrate, Isosorbide,Iso Bid,IsoBid,Isoket Retard 120,Isoket Retard120
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
The long-acting hemodynamic effects of isosorbide dinitrate.
April 1972, The American journal of cardiology,
T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
Isosorbide dinitrate oral spray in acute exacerbation of chronic congestive heart failure secondary to coronary artery disease.
May 1987, The American journal of cardiology,
T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
[The effect of isosorbide dinitrate spray on patients receiving coronary artery bypass grafting].
August 1991, Kyobu geka. The Japanese journal of thoracic surgery,
T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
Effects of isosorbide dinitrate spray on central hemodynamics. Comparison with sublingual glyceryl trinitrate and isosorbide dinitrate.
January 1984, Arzneimittel-Forschung,
T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease.
February 1992, Thrombosis research,
T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
[Hemodynamic effects of a new long-acting isosorbide dinitrate].
November 1985, Schweizerische medizinische Wochenschrift,
T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
Assessment of antianginal efficacy of long-acting sustained release isosorbide dinitrate in comparison with short-acting isosorbide dinitrate.
January 1991, Indian heart journal,
T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
Comparative hemodynamic effects of placebo and oral isosorbide dinitrate in patients with significant coronary artery disease.
July 1975, American heart journal,
T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
[Bioavailability of long-acting isosorbide dinitrate in humans].
January 1980, Bollettino della Societa italiana di cardiologia,
T Maeda, and T Saikawa, and H Niwa, and N Simoyama, and K Kohmatsu, and H Yonemochi, and T Inoue, and T Maruyama, and R Takaki, and Y Fukuoka
Coronary artery dilation and hemodynamic responses after isosorbide dinitrate therapy in patients with coronary artery disease.
September 1985, The American journal of cardiology,
Copied contents to your clipboard!